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Background: Recent clinical observation reported that there 
was a significant correlation between change in circulating 
vascular endothelial growth factor (VEGF) levels and the oc-
currence of severe acute graft-versus-host disease (GVHD) 
following allogeneic hematopoietic stem cell transplantation 
(allo-HSCT), but the action mechanisms of VEGF in GVHD 
have not been demonstrated. Methods: This study inves-
tigated whether or not blockade of VEGF has an effect on 
acute GVHD in a lethally irradiated murine allo-HSCT model 
of B6 (H-2
b) →B6D2F1 (H-2
b/d). Syngeneic or allogeneic re-
cipient mice were injected subcutaneously with anti-VEGF 
peptides, dRK6 (50μg/dose) or control diluent every other 
day for 2 weeks (total 7 doses). Results: Administration of 
the dRK6 peptide after allo-HSCT significantly reduced sur-
vival with greaterclinical GVHD scores and body weight loss. 
Allogeneic recipients injected with the dRK6 peptide ex-
hibited significantly increased circulating levels of VEGF and 
expansion of donor CD3
＋ T cells on day ＋7 compared to 
control treated animals. The donor CD4
＋ and CD8
＋ T-cell 
subsets have differential expansion caused by the dRK6 
injection. The circulating VEGF levels were reduced on day 
＋14 regardless of blockade of VEGF. Conclusion: Together 
these findings demonstrate that the allo-reactive responses 
after allo-HSCT are exaggerated by the blockade of VEGF. 
VEGF seems to be consumed during the progression of 
acute GVHD in this murine allo-HSCT model.
[Immune Network 2011;11(6):368-375]
INTRODUCTION
Allogeneic  hematopoietic  stem  cell  transplantation  (allo- 
HSCT) is the treatment of choice for manyhematological ma-
lignancies as well as for severe immunodeficiency. However, 
the main causes of patient mortality and morbidity after al-
lo-HSCT  are relapse,  graft-versus-host disease  (GVHD), and 
infections  (1,2).  Various  complications  occurring  after  al-
lo-HSCT  are  believed  to  be  manifestations  of  systemic  in-
flammatory response syndrome (SIRS) (3). SIRS is caused by 
hypercytokinemia  with  the  excess  production  of  proinflam-
m a t o r y  c y t o k i n e s  ( 4 ) .  I t  i s  g e n e r a l l y  r e c o g n i z e d  t h a t  c r o s s -  
linking  of  the  cytokine  network  plays  an  important  role  in 
t h e  i n f l a m m a t o r y  p r o c e s s e s .  D y s r e g u l a t i o n  o f  c y t o k i n e  p r o-
duction may initiate and perpetuate tissue damage in those 
who  undergo  allo-HSCT.
  Organ impairment in SIRS is believed to occur as a sequel 
to  vascular  endothelial  damage  (5).  Vascular  endothelial 
growth factor (VEGF) is a dimeric glycoprotein that increases 
the  vascular  permeability  and  induces  the  proliferation  and 
migration  of  endothelial  cells  to  form  new  blood  vessels 
(6,7). The role of angiogenesis in sustaining aninflammatory 
response has recently become evident. VEGF acts as a potent 
chemo-attractant  for  leukocytes  into  neovascularization  site 
and induces endothelial cells to produce collagenase. VEGF 
has also been implicated in a variety of chronic inflammatory Blockade of VEGF in GVHD
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diseases (8), and is intimately linked to the cytokine network 
because its expression is up-regulated by a number of cyto-
kines and growth factors. Moreover, a recent study reported 
an increased expression of cytochemokines, including MCP-1, 
IL-8, TNF-α and IL-1β, in peripheral blood monocytes treat-
ed with the placental growth factor (9), which has a remark-
ably  similar  three-dimensional  structure  to  VEGF  (10). 
    VEGF might be one of principal factors regulating the im-
mune reactions associated with acute and/or chronic GVHD 
(11). Recently, we have demonstrated that VEGF might play 
a role in GVHD protection, and the early change in the serum 
VEGF  level  may  be  a  surrogate  marker  for  life-threatening 
acute GVHD (12). Through the screening of peptide libraries, 
a soluble arginine-rich hexapeptide sequence, anti-VEGF pep-
tide dRK6 which could bind to VEGF and thereby block the 
i n t e r a c t i o n  b e t w e e n  V E G F 1 6 5  a n d  t h e  V E G F  r e c e p t o r  ( V E -
GFR) has been introduced (13). Based on these data, we ex-
amined the effect of blocking VEGF in vivo after allo-HSCT 
using a well-established murine allo-HSCT model of human 
GVHD. This study demonstrated that the clinical severity and 
donor T cell allo-reactivity of acute GVHD were aggravated 
b y  t h e  b l o c k a d e  o f  V E G F  i n  e a r l y  p o s t  a l l o - H S C T .
MATERIALS AND METHODS
Mice and reagents
Female  C57BL/6  (B6,  H-2
b,  CD45.2
＋),  B6.Ly-5a  (CD45.1
＋) 
and  B6D2F1  (H-2
b/d,  CD45.2
＋)  mice  were  purchased  from 
Japan SLC Inc. (Shizuoka, Japan). The age of the mice ranged 
from 8 to 12 weeks. The mice were housed in sterilized mi-
c r o i s o l a t o r  c a g e s  a n d  r e c e i v e d  f i l t e r e d  w a t e r  a n d  n o r m a l  
chow or autoclaved hyperchlorinated drinking water for the 
first  3  weeks  after  the  allo-HSCT.  The  anti-VEGF  peptide, 
dRK6  was  synthesized  at  the  Pohang  University  of  Science 
and Technology in Korea, as described previously (13). The 
human  recombinant  VEGF165 w a s  p u r c h a s e d  f r o m  R & D  
Systems  (Flanders,  NJ,  USA).
Experimental allo-HSCT and assessment of acute 
GVHD
The  mice  underwent  transplantation  according  to  standard 
protocol described previously (14,15). Briefly, the recipients 
received  a  single  dose  of  1,100  cGy  total  body  irradiation 
(TBI; cesium Cs 137 [
137Cs] source). T cell-depleted bone mar-
row (BM) cells (10×10
6) and 20×10
6 splenocytes from the 
respective allogeneic or syngeneic donors were resuspended 
and injected intravenously into the recipient animals on day 
0. Depletion of BM T cells in BM was performed using rele-
vant MicroBeads and MACS system (Miltenyi Biotec, Bergisch 
Gladbach, Germany), as a instruction of manual. The CD45.1
＋ 
B6Ly-5a  mice  were  used  as  donors  for  the  donor  cell  ex-
pansion  or  engraftment  experiments.  The  recipient  B6D2F1 
underwent transplantation with BM and splenocytes from al-
logeneic B6 or syngeneic B6D2F1 donors, respectively. Each 
experiment was conducted on 3 or 6 animals per group. The 
survival  was  monitored  daily,  and  the  body  weights  and 
G V H D  c l i n i c a l  s c o r e s  o f  t h e  r e c i p i e n t s  w e r e  m e a s u r e d  
weekly. The degree of systemic acute GVHD was assessed 
usinga scoring system that incorporates 5 clinical parameters: 
weight loss, posture (hunching), activity, fur texture, and skin 
integrity.  This  scoring  system i s  m o r e  a c c u r a t e  t h a n  j u s t  
weight loss alone, as described previously (16). At the time 
of analysis, the mice from coded cages were evaluated and 
graded from 0 to 2 for each of the criteria. A clinical index 
w a s  s u b s e q u e n t l y  g e n e r a t e d  b y  a d d i n g  t h e  s c o r e s  o f  t h e  5  
criteria  (maximum  index,  10).
Anti-VEGF peptide, dRK6 treatment
To determine the in vivo effect of VEGF blockade on the se-
verity of acute GVHD, syngeneic or recipient mice were in-
j e c t e d  s u b c u t a n e o u s l y  w i t h  t h e  d R K 6  p e p t i d e s  o r  c o n t r o l  
diluent. The recipient mice were injected with 50μg of the 
dRK6,  dissolved  in  phosphate  buffered  saline  (PBS,  Gibco, 
Grand Island, NY), and control with PBS alone. It has been 
previously shown that serum levels of the inflammatory cyto-
kines associated with the severity of GVHD after major histo-
compatibility  complex  (MHC)  class  I-  and  II-  disparate  al-
lo-HSCT  (B6,  H-2
b→B6D2F1,  H-2
b/d)  with  lethal  irradiation 
peaked  on  day  ＋7  and  decreased  thereafter  until  on  day 
＋14  (17).  Because  VEGF  may  be  associated  with  infla-
mmatory reactions in early post allo-HSCT, the dRK6 was in-
jected subcutaneously into HSCT recipients for 14 days from 
day 0 to day ＋14 every other day (total 7 injections) to de-
termine if it influences the severity of acute GVHD, whereas 
control mice received identical injections of the diluent. The 
dose of dRK6 was chosen for its ability to modulate an in-
flammatory disease, collagen-induced arthritis (CIA), in anoth-
er  model  (18).
Histologic examinations
At  day  ＋28,  mice  were  killed  for  histological  analysis. 
Formalin preserved skin, liver and intestine were embedded Blockade of VEGF in GVHD
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Figure 1. Treatment with anti-VEGF dRK6 peptide aggravates acute 
GVHD mortality. Effect of dRK6 on survival  in experimental acute 
GVHD induced across MHC class I and II. B6D2F1 mice received
1100 cGy TBI and underwent transplantation with 10×10
6 BM cells
and 20×10
6 splenocytes from allogeneic B6 (Allo, ■ and ●,  n=
12, respectively) or syngeneic F1 donors (Syn, ▲ and  ▼, n=6, 
respectively).  Recipient animals were injected subcutaneously with 
either 50 μg dRK6  per mouse (■ and ▲) or the diluent (● and 
▼) every other day from day 0 to day +14 (total 7 doses). Survival
was evaluated as detailed in “Materials and Methods”. Data from 2 
similar experiments are combined. ■ vs  ●, p=0.012.
in  paraffin,  cut  into  5-μm-thick  sections,  and  stained  with 
hematoxylin and eosin for histologic examination. Slides were 
coded without reference to prior treatment and examined in 
a blinded fashion by a pathologist. A semi-quantitative scor-
ing  system  was  used  to  assess  the  following  abnormalities 
known  to  be  associated  with  GVHD.  The  skin  was  scored 
for atrophy (0, 1, 2 and 3) and lymphocyte infiltration (0, 1 
and  2).  The  liver  was  scored  for  lymphocyte  infiltration  at 
the portal area (0, 1, 2, 3 and 4). The intestine was scored 
for number of crypt apoptotic cells per 10 gland area (0, 0.5, 
1, 2, 3, 4 and 5). The scoring system denoted 0 as＜2, 0.5 
as 2∼5, 1 as＜30%, 2 as 30∼70%, 3 as＞70%, 4 as moderate 
apoptosis in all glands, and 5 as severe apoptosis in all glands 
(19).
Flow cytometric analysis
All  the  antibodies  including  phycoerythrin  (PE)-conjugated 
anti-CD3  monoclonal  antibody  (mAb),  fluorescein  isothi-
ocyanate  (FITC)-conjugated  anti-CD4  mAb,  FITC-conjugated 
anti-CD8  mAb  and  APC-conjugated  anti-CD45.1  mAb  were 
purchased from BD Pharmingen (San Diego, CA, USA). The 
procedure  was  performed  as  described  elsewhere  (19). 
Briefly, the cells were first incubated with mAb 2.4G2 for 15 
minutes at 4
oC and then with the relevant FITC- or PE-con-
jugated  mAb  for  30  minutes  at  4
oC.  Finally,  the  cells  were 
washed  twice  with  PBS/0.2%  bovine  serum  albumin  and 
fixed  with  PBS/1%  paraformaldehyde.  Flow  cytometry  was 
performed using a FACSVantage SE cell sorter (BD Bioscien-




＋) was used to evaluate the expansion 
o f  d o n o r  T  c e l l s  a f t e r  a l l o - H S C T .
Cytokine enzyme-linked immunosorbent assay (ELI-
SA)
The amount of the cytokines (IFN-γ, TNF-α and VEGF) in 
t h e s er a o f r ec ip ie nt  m ic e  wa s m e asu re d  by  E LI SA  u sin g  a 
commercially available k it (R&D Systems, Minneapolis, MN , 
USA). The samples and standards were run in duplicate. The 
absorbance at 450 nm was measured using a microplate spec-
trophotometer,  Benchmark  Plus  (Bio-Rad,  Richmond,  CA, 
USA).
Statistical analysis
A Mann-Whitney U test was used for the statistical analysis 
of the cytokine data, clinical GVHD scores and the number 
of cells, whereas the Wilcoxon rank test was used to analyze 
the survival data. The statistical significance was considered 
a s  p  v a l u e  b e l o w  0 . 0 5 .
RESULTS
Administration of dRK6 aggravated the severity of 
acute GVHD after experimental allo-HSCT
As shown in Fig. 1, injection of dRK6 after the B6→6D2F1 
allo-HSCT accelerated the GVHD mortality. Allo-HSCT recipi-
ents injected dRK6 exhibited mortality more rapidly than con-
trols with 10% of animals surviving by day ＋50, while the 
control allogeneic group mice exhibited 30% survival at the 
end of 50-day observation period (p=0.012). Animals that un-
derwent  syngeneic  B6D2F1→B6D2F1  (syn-)  HSCT  showed 
100% survival irrespective of the dRK6 injections, which ruled 
out  any  nonspecific  toxicities  of  the  conditioning  and  the 
dRK6 peptide injection. Fig. 2A shows that clinical GVHD in 
the  allogeneic  recipients  receiving  dRK6  was  more  severe 
than  in  control  mice  (p＜0.05).  As  expected,  scores  for 
syn-HSCT recipients gradually returned to baseline by week 
＋2. The body weight loss of recipients of each group which 
also correlates with the severity of acute GVHD. Consistent 
with the increased acute GVHD-related mortality and the clin-Blockade of VEGF in GVHD
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(A) (B)
Figure 3. (A) A representative of histopathology of liver, intestine and skin. (B) Histologic scoring. Animals that underwent transplantation 
(n=4/group) were killed; liver, intestine and skin were obtained for analysis on day +28 after HSCT. Coded slides were semi-quantitative to 
assess pathologic damage, as described in “Materials and Methods”. Total GVHD score; mean±SE of the sum of scores for tissues from individual 
animals in each group.                         
Figure 2. Treatment with anti-VEGF dRK6 peptide aggravates acute GVHD-specific morbidity. Effect of dRK6 on acute GVHD score (A) and
change of body weight (B) in experimental acute GVHD induced across MHC class I and II. B6D2F1 mice received 1100 cGy TBI and underwent
transplantation with 10×10
6 BM cells and 20×10
6 splenocytes from allogeneic B6 (Allo, ■ and ●,  n=12, respectively) or syngeneic F1 donors
(Syn,  ▲ and  ▼, n=6, respectively). Recipient animals were injected subcutaneously with either 50μg dRK6  per mouse (■ and  ▲) or the
diluent (● and ▼) every other day from day 0 to day +14 (total 7 doses). GVHD score was evaluated as detailed in “Materials and Methods”.
Mean±SE is shown. Data from 2 similar experiments are combined. *p<0.05.
ical GVHD scores, the dRK6 injection caused significantly se-
vere weight loss compared with the controls (p＜0.05) (Fig. 
2B).
  Fig. 3A shows that the allogeneic recipients had significantly 
more histopathologic tissue damage on day ＋28 compared 
with the syngeneic recipients. We observed that heavy lym-
phocyte infiltration at the hepatic portal areas as well as in-
testinal  epithelium  apoptosis  in  allogeneic  recipients,  but  a 
f e w  d a m a g e  w a s  f o u n d  i n  t h e  l i v e r  o f  t h e  s y n g e n e i c  
recipients.  In  addition,  we  observed  epidermal  hyperplasia 
and lymphocyte infiltration in thedermis in the skin of alloge-
neic animals compared to syngeneic recipients. Recipients of Blockade of VEGF in GVHD
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Figure 4. Effect of dRK6 on donor T-cell expansion after allo-HSCT. B6D2F1 (Allo) or B6 (Syn) mice received 1100 cGy 
TBI and underwent transplantation with 10×10
6 BM cells and 20×10
6 splenocytes from allogeneic B6.Ly-5a (CD45.1
+) donors
as in Fig. 1. Allogeneic recipient were injected subcutaneously with either 50μg dRK6 per mouse or the diluent as described
in “Materials and Methods”. (A-C) Splenocytes were harvested on day +7 from the recipints (n=4/group) and labeled with
anti-CD45.1
+ APC and anti-CD3
+ PE (A), anti-CD4
+ FITC (B) or anti-CD8




+ cells was determined by flow cytometry. dRK6 significantly increased donor CD3
+ and CD4
+ expansion but not
CD8
+ expansion (*p<0.05). 
the dRK6 injections, however, differed little from the controls 
in allogeneic or syngeneic recipients, respectively (Fig. 3B). 
Thus, the injection of dRK6 in this allo-HSCT model was asso-
ciated with increased severity of acute GVHD, as determined 
by survival and clinical parametersbut not by the pathologic 
grading. Histologic examination demonstrated that this mur-
ine allo-HSCT model was adequately established to observe 
the occurrence of acute GVHD, which are similar to human 
GVHD.
Effect of dRK6 on donor T-cell expansion after 
allo-HSCT
All  the  recipient  animals  displayed  complete  donor  hema-
topoietic  chimerism,  as  determined  by  FACS  analysis  (data 
not  shown).  The  administration  of  dRK6  significantly  en-
hanced donor CD3
＋ T-cell expansion in the recipient spleens 
on day ＋7 (16.1±2.7% vs 10.5±2.0%, Fig. 4A; p=0.047) in 
this lethally irradiated murine allo-HSCT model of B6 (H-2
b) 
→6D2F1  (H-2
b/d) .  A s  s h o w n  i n  F i g .  4 B  a n d  4 C ,  d R K 6  i n -
jection more clearly enhanced the expansion of donor CD4
＋ 
T cells (8.3±1.4% vs 5.9±1.5%; p=0.091) compared to that 
of donor CD8
＋ T-cell subsets. Donor CD8
＋ T-cell expansion 
by the administration of either the dRK6 or the PBS was sim-
ilar  (9.2±1.4%  vs  8.2±2.4%;  p=0.385). 
Serum VEGF concentrations after allo-HSCT
The  circulating  VEGF  concentrations  on  day  ＋7  were  sig-
nificantly elevated in recipients of dRK6 than in the controls 
(108±6.5 pg/ml vs 78±3.6 pg/ml, p=0.005) whereas VEGF 
levels  at  later  time  (on  day  ＋14)  were  similar  between Blockade of VEGF in GVHD
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Figure 5. Effect of dRK6 on the kinetics of serum VEGF concentrations  and VEGF  protein expressions in 
mouse liver after allo-HSCT.  B6D2F1 (Allo) or B6 (Syn) mice received 1100 cGy TBI and underwent trans-
plantation with 10×10
6 BM cells and 20×10
6 splenocytes from allogeneic B6. Ly-5a (CD45.1
+) donors as 
in Fig. 1. Allogeneic recipient were injected subcutaneously with either 50μg dRK6 per mouse or the diluent 
as described in “Materials and Methods”. Sera from the recipient animals were obtained on days +7 and 
+14 after transplant and were analyzed for VEGF as describe in “Materials and Methods” (*p=0.005). 
analyzed for VEGF as describe in “Materials and Methods” (*p=0.005).
groups (14±1.0 pg/ml vs 12±0.5 pg/ml, p＞0.05) (Fig. 5A). 
Both TNF-α and IFN-γ serum levels were not significantly 
higher  at  day  ＋7  and  ＋14  in  allogeneic  animals  injected 
with  dRK6  compared  with  the  control  animals  (data  not 
shown). 
DISCUSSION
It was previously demonstrated that vascular endothelial dam-
age  and  hypercytokinemia  are  involved  in  acute  GVHD, 
which means that VEGF may also play a major role in modu-
lating the graft-versus-host reactions among the many mani-
festations of SIRS (20-23). However, the mechanism by which 
VEGF functions in acute GVHD remains controversial. Lunn 
et al.(11) reported that serum VEGF levels were significantly 
raised in patients with GVHD compared with those who did 
not  develop  GVHD.  However,  Min  et  al.(12)  demonstrated 
that there was a significant correlation between a low VEGF 
level  and  the  occurrence  of  severe  acute  GVHD  including 
grade III-IV. In the current study, we tested whether the dRK6 
peptide  treatment  affected  acute  GVHD  and  explored  the 
mechanisms of VEGF on the development of acute GVHD us-
ing a murine allo-HSCT model. Our results demonstrate that 
the high circulating levels of VEGFand magnified donor T-cell 
expansion caused by the blockade of the interaction between 
VEGF and VEGFR following the injections of the anti-VEGF 
peptide, dRK6, early after transplant are associated with the 
aggravation of acute GVHD mortality after murine allo-HSCT. 
Although  dRK6  injection  do  not  directly  increase  the  pro-
duction  of  pro-inflammatory  cytokines  such  as  TNF-α and 
IFN-γ,  which  have  been  importantly  implicated  in  acute 
GVHD (24,25), the increased VEGF concentrations early after 
allo-HSCT suggest that VEGF may play an important role in 
the  occurrence  of  acute  GVHD.
  Our results are partly in line with the previous report that 
high circulating levels of VEGF were associated with the atte-
nuated  severity  of  acute  GVHD  leading  to  a  lower  non-re-
lapse mortality in human data (12). In these experiments, se-
rum VEGF levels on day ＋7 were significantly higher after 
administration of dRK6, but those on day ＋14 became de-
creased and similar irrespective of a large dose of dRK6 in-
jections (Fig. 5). These results indicate that consumption of 
VEGF in GVHD target tissues may be augmented in the allo-
geneic recipients that experienced more severe acute GVHD 
caused  by  administration  of  dRK6.  Moreover,  the  local  ex-
pressions of hepatic VEGF protein between day ＋7 and day 
＋14 have a tendency to increase in the allogeneic recipients 
with no respect to the VEGF blockade (data not shown). We 
postulate that circulating VEGF in early posttransplant was ex-
cessively used during the occurrence of acute GVHD, indicat-Blockade of VEGF in GVHD
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ing that a condition of low VEGF expression after allo-HSCT 
may be associated with aggravation of the severity of acute 
GVHD. 
    It  has  been  shown  that  the  dRK6  strongly  inhibited 
VEGF-induced  angiogenesis  with  retarded  growth  of  tumor 
cells (13) and the severity of CIA (18). In our study, it is re-
markable  that,  on  the  contrary,  the  administration  of  dRK6 
in  a  well-established  B6  (H-2
b)→B6D2F1  (H-2
b/d)  acute 
GVHD model was associated with the higher mortality and 
morbidity. Indeed, acute GVHD mediated mainly by CD4
＋T 
cells can be inhibited by the early administration of pro-in-
flammatory cytokines such as IFN-γ, IL-2, IL-12, and IL-18 
(19,26-28).  The  reason  why  the  severity  of  acute  GVHD  is 
attenuated is attributed to the fact that the pro-inflammatory 
cytokines cause Fas-dependent apoptosis of donor CD4
＋ T 
cells rather than donor CD8
＋ T cells. In this allo-HSCT model 
in which acute GVHD is also mainly mediated by CD4
＋ T 
cells, the administration of dRK6 inhibited the biological effect 
of  VEGF  which  may  inhibit  CD4
＋  T-cell  mediated  GVHD. 
Our  data  indicated  that  the  donor  CD4
＋ a n d  C D 8 ＋ T-cell 
subsets showed a trend toward differential expansion caused 
by the dRK6 injection. Allogeneic recipients with dRK6 ad-
ministration had a tendency to show a greater donor CD4＋ 
T-cell  expansionin  spleen  compared  to  those  injected  the 
control diluent, but donor CD8＋T-cell expansion by the ad-
ministration of either the dRK6 or the PBS was similar (Fig. 
4B and C). Therefore, caution must be exercised before ap-
plying  cytokine  manipulation  in  general  to  the  clinical  sit-
uation  in  which  both  T-cell  subsets  play  an  important  role 
in  mediating  GVHD.
    One of the earliest physiological responses to a tissue in-
jury or infection is an increase in vascular permeability and 
blood flow to the affected area, which initiated by regional 
vasodilation followed by enhanced angiogenesis to facilitate 
the wound healing process (29). Cytokine signaling also plays 
an important role in the angiogenic response to wound repair 
and  infection.  VEGF  is  an  endothelial  cell-specific  mitogen 
with an ability to promote angiogenesis (30). As wound ma-
turation  progress,  additional  angiogenesis  is  induced  by  in-
creasing tissue levels of VEGF, which peak several days after 
injury.  Anti-angiogenesis  treatment  with  anti-VEGF  peptide, 
dRK6 may prevent wound repair by blocking wound healing 
effect of VEGF in the GVHD target organs and increase the 
GVHD-associated  morbid i t y  a n d  m o r t a l i t y .  
    In conclusion, the administration of dRK6 peptide after al-
lo-HSCT  aggravates  the  morbidity  and  mortality  of  acute 
GVHD  by  means  of  increased  circulating  VEGF  production 
and  donor  T-cell  expansion  early  after  transplant.  The  ki-
netics of circulating VEGF levels earlyafter allo-HSCT showed 
that VEGF may have an important role in the pathophysiology 
of GVHD by being consumed during development of acute 
GVHD.
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